Frank T. Watkins - Jan 8, 2024 Form 4 Insider Report for Shockwave Medical, Inc. (SWAV)

Role
Director
Signature
/s/ Wade Estey, as attorney-in-fact for Frank T. Watkins
Stock symbol
SWAV
Transactions as of
Jan 8, 2024
Transactions value $
-$391,143
Form type
4
Date filed
1/10/2024, 08:10 PM
Previous filing
Nov 21, 2023
Next filing
Feb 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SWAV Common Stock Options Exercise $6.83K +2K +44.13% $3.42* 6.53K Jan 8, 2024 Direct F1
transaction SWAV Common Stock Sale -$39.2K -200 -3.06% $196.15 6.33K Jan 8, 2024 Direct F1, F2
transaction SWAV Common Stock Sale -$139K -700 -11.05% $197.94 5.63K Jan 8, 2024 Direct F1, F3
transaction SWAV Common Stock Sale -$220K -1.1K -19.53% $200.17 4.53K Jan 8, 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SWAV Stock Option Options Exercise $0 -2K -2.21% $0.00 88.3K Jan 8, 2024 Common Stock 2K $3.42 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 9/5/2023.
F2 All reported securities were sold at a price of $196.15.
F3 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $197.85 to $198.35. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F4 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $199.78 to $200.28. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F5 Fully vested.